Rehovot, Israel, January 4, 2010

Foamix Ltd., a leading developer of topical foams for dermatological and gynecological use, announced today it has been selected as a finalist for Red Herring's Global 100 award, a prestigious list honoring the year’s most promising private technology ventures from around the world.

The Red Herring editorial team selected the most innovative companies from a pool of 1,200. The nominees are evaluated on both quantitative and qualitative criteria, such as financial performance, technology innovation, quality of management, execution of strategy, and integration into their respective industries.

This unique assessment of potential is complemented by a review of the actual track record and standing of a company, which allows Red Herring to see past the “buzz” and make the list an invaluable instrument for discovering and advocating the greatest business opportunities in the industry.

“We are excited to be recognized by Red Herring on a global scale for our continued innovation and success,” said Dr. Dov Tamarkin, CEO of Foamix. “The Red Herring Global Award is an endorsement of our breakthrough technology, intellectual property and corporate partnerships with industry leaders.”

"This year was especially difficult," said Alex Vieux, publisher and CEO of Red Herring. "Despite the global economic situation, there were many great companies producing really innovative and amazing products that we had a difficult time narrowing the pool and selecting the finalists. Now we’re faced with the arduous task of selecting the final 100 winners of the award. We know that this year’s crop will grow into some amazing companies that are sure to go far."

Finalists for the 2009 edition of the Red Herring Global 100 award are selected from the regional recipients or finalists of the Red Herring 100 awards in 2007, 2008, or 2009 ranging from Asia, Europe, and North America. For the past three years, the award has been given to the top 100 global technology companies based upon their technological innovation, management strength, market size, investor record, customer acquisition, and financial health. During the several months leading up to the announcement, hundreds of companies in the telecommunications, security, Web 2.0, software, hardware, biotech, and clean tech industries sent in their submissions to qualify for the award.

About Foamix:

Headquartered in Rehovot, Israel, Foamix Ltd. is a leading developer of topical and mucosal foams for dermatological and gynecological applications. Foamix’s state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is currently collaborating with pharmaceutical and cosmetic companies on a range of projects in the development of proprietary dermatological and gynecologic foam products. Additionally, the Company has an in-house pipeline of dermatological and gynecological formulations in foam presentation. Foamix’s psoriasis foam product licensed to Dr. Reddy's Laboratories, Inc and marketed by Promius Pharma under the trade mark Scytera™ was launched in the United States in early 2009

Foamix has eighteen issued patents worldwide covering its foam and OilGel technology platforms and over 150 pending applications of which more than a third are filed in the United States.

For additional information please visit www.foamix.co.il

About Red Herring:

Red Herring is a global media company uniting the world's best high-technology innovators, venture investors, and business decision-makers in a variety of forums: a leading innovation magazine, an online daily technology news service, technology newsletters, and major events for technology leaders around the globe. Red Herring provides an insider's view of the global innovation ecosystem, featuring unparalleled insights on the emerging technologies driving the economy.

For more information contact Anam Alpenia at: aalpenia@redherring.com